Bankers are putting together major financing packages in preparation of a potential private equity bid for GlaxoSmithKline’s consumer healthcare business, according to reports.
Lenders are reportedly modelling debt packages of between £20bn and £25bn in sterling, dollars and euro, according to Bloomberg, after it emerged that GSK had rebuffed three cash-and-share approaches from Marmite-maker Unilever last year.
Analysts have said that Unilever’s offer has put GSK’s consumer group in the shop window and a number of other consumer firms will be sizing up the business as a potential fit.
Read more/Source: City AM
